

REGISTER BY 19TH DECEMBER AND RECEIVE A £300 DISCOUNT  
REGISTER BY 22ND FEBRUARY AND RECEIVE A £100 DISCOUNT

# SMi present their 9th annual conference on... **Asthma & COPD**

15th and 16th April 2013, Copthorne Tara Hotel, London, UK

## KEY SPEAKERS INCLUDE:

### Peter Barnes

Head of Respiratory Medicine  
Imperial College School of Medicine

### Sebastian Johnston

Professor of Adult Respiratory Medicine  
Imperial College

### Matthew Catley

Team Leader R&I  
AstraZeneca

### Emma Hickman

Research Investigator  
Novartis

### Ewan Walters

Head of Clinical Science  
Respiratory/Immunology  
TEVA

### Donna Finch

Associate Director/Principle Scientist  
MedImmune

### Liz Hardaker

Investigator II  
Novartis

### Christopher Stevenson

Research Leader  
Roche

### Mary Fitzgerald

Executive VP Respiratory  
Pulmagen

### Geoff Down

Chief Medical Officer  
Prosonix

## KEY TOPICS FOR 2013:

- Establishing **patient phenotyping** for efficient and effective therapeutic outcomes
- Overcoming the challenges of **clinical trial management** and developing novel **biomarkers**
- Spotlight on **inhalation devices** and combination therapies
- Comparing and contrasting **exacerbations** of asthma & COPD alongside treatment options
- Drawing attention to **chemokine antagonists** and **anti-cytokine** therapies
- Overcoming **steroid resistance** in asthma & COPD

Sponsored by



**PLUS ONE INTERACTIVE HALF-DAY POST CONFERENCE WORKSHOP**  
Wednesday 17th April 2013, Copthorne Tara, London, UK

## Clinical Trial Design in Asthma & COPD

Workshop Leader:

Kevin Bacon, Chief Scientific Officer, Axikin

08.30am – 12.30pm

TO BOOK

[www.asthma-copd.co.uk](http://www.asthma-copd.co.uk)

Register online and receive full information on all of SMi's conferences

Alternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711



08.30 Registration and Coffee

09.00 **Chairman's Opening Remarks**

**Peter Barnes**, Head of Respiratory Medicine, **Imperial College School of Medicine**

### STEROID RESISTANCE AND ASTHMA MANAGEMENT

09.10 **The problem of steroid resistance in asthma and COPD**

- Corticosteroid resistance is a major barrier to effective treatment of severe asthma and COPD
- The molecular mechanisms of corticosteroid resistance are now much better defined
- This understanding identifies new therapeutic targets that may lead to reversal of steroid resistance
- Several existing and new drugs are being developed for reversing steroid resistance in asthma and COPD

**Peter Barnes**, Head of Respiratory Medicine, **Imperial College School of Medicine**

09.50 **Risk and control in the management of asthma**

- What is the difference between risk and control in asthma?
- How do we identify those at risk of an asthma attack?
- Helping people with asthma reduce their risk and improve asthma control
- Implications for asthma management

**Samantha Walker**, Executive Director, Research & Policy, **Asthma UK**

10.30 Morning Coffee

### PRECLINICAL DEVELOPMENT

11.00 **Patient stratification in the development of biologicals**

- Asthma patient phenotypes
- Periostin and anti-IL-13
- Mepolizumab
- Mechanistic endotypes

**Matthew Catley**, Team Leader R&I, **AstraZeneca**

11.40 **Innovative approaches to developing preclinical models for COPD and asthma**

- Insights gained from careful characterisations of preclinical models
- Novel bioinformatics methods for comparing preclinical models to clinical samples
- The importance for routinely assessing changes in lung physiology in these preclinical models

**Christopher Stevenson**, Research Leader, **Roche**

12.20 **Immunotherapy for asthma**

- Replication of regulatory processes that occur in non-asthmatic individuals
- Current and future methodologies for immunotherapy
- Immunotherapy with Omalizumab
- Immunotherapy for long-lasting treatment without immunosuppression or immune augmentation

**Emma Hickman**, Research Investigator, **Novartis**

13.00 Networking Lunch

### CLINICAL TRIAL STUDIES

14.20 **New controller therapies for asthma: From small molecules to monoclonal anti-bodies**

- New controller therapies for asthma; what is on the horizon?
- CRTh2 antagonists; new controller therapies for asthma
- Different combination approaches for asthma therapy; not just alternative ICS/LABAs

**Mary Fitzgerald**, Executive VP Respiratory, **Pulmagen**

15.00 **CRTH2 antagonists: basic biology and clinical effects**

- Role of CRTH2 in mediating allergic disease
- Pharmacological profile of the CRTH2 antagonist OC000459
- Clinical effects of OC000459 in asthma and allergic rhinoconjunctivitis

**Roy Pettipher**, Director of Pharmacology, **Oxagen**

15.40 Afternoon Tea

16.00 **Discovery and Development of small molecule CCR3 inhibitors for asthma and allergic rhinitis**

- Agonism of CCR3 and its role in allergic inflammation
- Pharmacologic activity of small molecular weight inhibitors in vitro and in vivo
- Clinical development

**Kevin Bacon**, Chief Scientific Officer, **Axikin**

16.40 **Panel Discussion: Asthma mechanisms AND treatments**

**Panel Chair:** **Peter Barnes**, Head of Respiratory Medicine, **Imperial College School of Medicine**

**Panellists:** **All Day One Speakers**

17.20 **Chairman's Closing Remarks and Close of Day One**

Register online at [www.asthma-copd.co.uk](http://www.asthma-copd.co.uk) • Alternatively fax y

#### Sponsored by



**Vitalograph** has manufactured respiratory diagnostic equipment for the healthcare industry since 1963 and the name Vitalograph is synonymous with spirometry around the world. The name Vitalograph is also synonymous with quality, as many of our spirometers in everyday use are more than 30 years old! As a consequence, our equipment is favoured by opinion leaders and clinical researchers who need reliable and accurate measurements. We provide a full range of services within respiratory clinical trials

and this includes project management, centralized data management, over-reading and a global 24/7 support service. We also have a dedicated integrated solution via our Spirotrac® Centralized Spirometry System that includes site based FeNO measurements, 6MWT, pulse oximetry, challenge testing, 12-lead ECG and our exciting new In2itive™ e-Diary that complies with FDA's PRO guidance with validated questionnaires. All data is accessible via our VIEWER™ web portal. Also ask about our unique new AIM inhaler trainer for pMDIs and DPIs! [www.vitalograph.co.uk](http://www.vitalograph.co.uk)

#### Supported by



08.30 Re-registration and Coffee

09.00 **Chairman's Opening Remarks**  
**Sebastian Johnston**, Professor of Adult Respiratory Medicine,  
**Imperial College School of Medicine**

**EXACERBATIONS AND PATIENT REPORTED OUTCOMES**

09.10 **Comparing exacerbations of Asthma & COPD alongside treatment options**

- Aetiology of exacerbations
- Modelling exacerbations in mouse & man
- Mechanisms of exacerbations
- Treatment of exacerbations

**Sebastian Johnston**, Professor of Adult Respiratory Medicine,  
**Imperial College School of Medicine**

09.50 **Developing preclinical models to mimic exacerbations of COPD and asthma**

- What are exacerbations of COPD and asthma?
- Current therapies to treat COPD and asthma exacerbations
- In vivo models that mimic aspects of COPD and asthma exacerbations

**Liz Hardaker**, Investigator II, **Novartis**

10.30 Morning Coffee

11.00 **Case study - A patient with recurrent COPD exacerbations - where is innovation needed to improve care?**

- Case presentation of a patient with recurrent exacerbations
- Examples of how new insights into disease and exacerbation phenotypes can improve care
- Horizon scanning for innovations to address treatment gaps

**Emma Baker**, Professor of Clinical Pharmacology, **St George's, University of London**

11.40 **Bacterial exacerbation of the altered lung**

- Asthma/COPD
- innate immunity
- anti-bacterial immunity
- Epithelium and airway macrophages

**Tracey Hussell**, Centre Director (MCCIR), **Manchester University**

12.10 Networking Lunch

**THERAPEUTIC APPLICATIONS AND PATHOGENESIS**

13.40 **Inhaler therapies to deliver ICS**

- Role in delivering active treatments to the lung
- Randomised Clinical Trials (RCTs)
- Modalities to assess PROs
- Overcoming challenges

**Ewan Walters**, Head of Clinical Science Respiratory/Immunology,  
**TEVA**

14.20 **Exploring the many credible molecular and cellular mechanisms of COPD pathogenesis**

- Exacerbations- balancing pathogen recognition and inflammation
- Emphysema- what drives lung destruction?
- Can both be linked via mechanistic hypotheses?

**Donna Finch**, Associate Director/Principal Scientist, **MedImmune**

15.00 Afternoon Tea

**INNOVATION AND FUTURE STRATEGIES**

15.20 **Pharmacodynamic Evaluation of Orally Inhaled Corticosteroids**

- Scientific and regulatory background
- Current issues
- Conventional and exploratory methods
- Interpretation and evaluation

**Geoff Down**, Chief Medical Officer, **Prosonix**

16.00 **Asthma/COPD - phenotypes, biomarkers and implication for stratified therapeutic approaches**

- Patient phenotypes
- Application of biomarkers
- Challenges of therapeutic approaches

**Harald Renz**, Professor of Laboratory Medicine, **Philipps-University of Marburg**

16.40 **Panel Discussion: COPD mechanisms AND treatments**

**Panel Chair: Sebastian Johnston**, Professor of Adult Respiratory Medicine, **Imperial College**

**Panellists: All Day Two Speakers**

17.20 **Chairman's Closing Remarks and Close of Day Two**

your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

**Who should attend this conference:**

*This event is unmissable for Chief Executives, Chief Scientific Officers, Presidents, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Research Fellows, Principal Investigators, Managers, Project/Team Leaders in:*

- Respiratory Medicine
- Respiratory Pharmacology
- Inflammatory Disease
- Research Immunology
- Pharmacology
- Respiratory Licensing
- Respiratory, Inflammation and Autoimmunity
- Pulmonary Disease
- Immunology
- Respiratory Cell Biology
- Respiratory Therapeutics
- Inhalation Devices
- Medical Devices
- Inflammation Discovery
- Respiratory Medicine Regulation

**SPONSORSHIP AND EXHIBITION OPPORTUNITIES**

SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company's marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

**Want to know how you can get involved? Interested in promoting your pharmaceutical services to this market?**

Contact Kellee Halliburton,  
 SMi Marketing on +44 (0) 207 827 6194,  
 or email khalliburton@smi-online.co.uk

**HALF-DAY POST-CONFERENCE  
AM WORKSHOP**  
**08.30am – 12.30pm**  
**Wednesday 17th April 2013**  
**Copthorne Tara Hotel, London, UK**

**Clinical Trial Design  
in Asthma & COPD**

Workshop Leader:

**Kevin Bacon**, Chief Scientific Officer, **Axikin**

In association with

**Axikin**

**Overview of workshop**

This workshop will be a unique interactive session where attendees can explore clinical trial design in asthma and COPD alongside emerging ideas and case studies that can be applied to their own roles and environments. Led by the expertise and experience of Kevin Bacon, of Axikin, the workshop will explore the challenges faced in clinical trial design and facilitate the understanding of unmet needs in clinical trial design for asthma & COPD alongside methods to overcome them.

**Why you should attend:**

- Discover the benefits of efficient clinical trial design
- Address and overcome the key challenges associated in phase II trials
- Evaluate past experiences and case studies and benefit from lessons learnt
- Network with key industry professionals

**Programme**

**08.30 Registration & Coffee**

**09.00 Welcome & Introductions**

**09.10 Anti-inflammatories for Asthma and COPD**

- Usual suspects and novel mechanisms
- NCEs vs antibodies

**09.45 Positioning Novel Anti-inflammatories**

- Clinical vs Pharma perspectives
- Stand-alones vs combination products

**10.45 Morning Refreshments**

**11.00 Pre-clinical Models for Novel Anti-inflammatories**

- Current practice and utility
- Translational considerations

**12.10 Discussion Session**

**12.30 Close of Workshop**

**About the workshop host**

As President and Chief Scientific Officer, Dr. Bacon brings almost 20 years of drug discovery, development and management experience to Axikin. Dr. Bacon, founded Axikin's predecessor, Actimis Pharmaceuticals, in 2004, as a spin-off from Bayer Yakuhin Ltd.'s Respiratory Research Department in Kyoto, Japan, where he served as Vice President of respiratory diseases research. He was latterly involved in negotiating the eventual sale, in a structured acquisition, of Actimis in June 2008, and the formation of Axikin to continue development of additional pre-clinical assets. Prior to joining Bayer AG in 1999, Dr. Bacon was Associate Director of Immunology at Neurocrine Biosciences, Inc., in San Diego, and from 1994 to 1997 a Visiting Scientist at the DNAX Institute for Molecular Biology (a subsidiary of Schering Plough). Dr. Bacon is a co-author on numerous issued and filed patents, actively contributes to journals' peer review process, and has published over 100 original manuscripts, book chapters and reviews in the field of drug discovery and inflammation biology.

**About Axikin**

With a rapidly growing portfolio of highly-optimized small molecules, Axikin is well-poised to draw upon significant in-house expertise in anti-inflammatory drug development to move its lead GPCR program towards an IND within an accelerated timeframe. In addition, Axikin has entered into strategic collaborations that will enable target validation, small molecule screening and lead optimization for its kinase program.

# SMI PHARMACEUTICAL FORWARD PLANNER 2013

## JANUARY

### **Biomarkers Summit**

16 – 17 January 2013, London

### **Social Media in the Pharma Industry**

23 – 24 January 2013, London

### **Quality by Design**

23 – 24 January 2013, London

### **Pre-Filled Syringes**

28 – 29 January 2013, London

### **Pharmaceutical Microbiology**

30 – 31 January 2013, London

## FEBRUARY

### **Parallel Trade**

6 – 7 February 2013, London

### **Advances and Progress in Drug Design**

18 – 19 February 2013, London

### **Lyophilisation - Freeze Drying in Pharmaceuticals and Biopharmaceuticals**

25 – 26 February 2013, London

## MARCH

### **Superbugs & Superdrugs - A Focus on Antibacterials**

4 – 5 March 2013, London

### **Imaging in Cancer Drug Development**

13 – 14 March 2013, London

### **Controlled Release**

18 – 19 March 2013, London

### **Paediatric Clinical Trials**

20 – 21 March 2013, London

## APRIL

### **Adaptive Designs**

8 – 9 April 2013, London

### **Asthma & COPD**

15 – 16 April 2013, London

### **Pharmaceutical Portfolio & Lifecycle Management**

17 – 18 April 2013, London

## MAY

### **Generics, Supergenerics & Patent Strategies**

13 – 14 May 2013, London

### **Pain Therapeutics**

20 – 21 May 2013, London

### **ADC Summit**

20 – 21 May 2013, London

### **Clinical Trial Logistics**

22 – 23 May 2013, London

## JUNE

### **RNAi & Nanotechnology**

5 – 6 June 2013, London

### **Biobanking**

24-25 June 2013, London

### **Allergies**

26 – 27 June 2013, London

### **ADMET**

26 – 27 June 2013, London

## JULY

### **Pharmacovigilance**

1 – 2 July 2013, London

### **Cell Culture**

3 – 4 July 2013, London

# ASTHMA & COPD

Conference: Monday 15th and Tuesday 16th April 2013, Copthorne Tara Hotel, London, UK

Workshop: Wednesday 17th April 2013, London, UK

## 4 WAYS TO REGISTER

www.asthma-copd.co.uk

FAX your booking form to +44 (0) 870 9090 712  
PHONE on +44 (0) 870 9090 711

POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South,  
Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK

--	--

Unique Reference Number	
Our Reference	LVP-064

### DELEGATE DETAILS

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: Forename: \_\_\_\_\_

Surname: \_\_\_\_\_

Job Title: \_\_\_\_\_

Department/Division: \_\_\_\_\_

Company/Organisation: \_\_\_\_\_

Email: \_\_\_\_\_

Company VAT Number: \_\_\_\_\_

Address: \_\_\_\_\_

Town/City: \_\_\_\_\_

Post/Zip Code: Country: \_\_\_\_\_

Direct Tel: Direct Fax: \_\_\_\_\_

Mobile: \_\_\_\_\_

Switchboard: \_\_\_\_\_

Signature: Date: \_\_\_\_\_

I agree to be bound by SMi's Terms and Conditions of Booking.

### ACCOUNTS DEPT

Title: Forename: \_\_\_\_\_

Surname: \_\_\_\_\_

Email: \_\_\_\_\_

Address (if different from above): \_\_\_\_\_

Town/City: \_\_\_\_\_

Post/Zip Code: Country: \_\_\_\_\_

Direct Tel: Direct Fax: \_\_\_\_\_

### Terms and Conditions of Booking

**Payment:** If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received.

**Substitutions/Name Changes:** If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not 'share' a place at an event. Please make separate bookings for each delegate.

**Cancellation:** If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regrettably cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.

**Alterations:** It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.

**Data Protection:** The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here  we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager [databasemanager@smi-online.co.uk](mailto:databasemanager@smi-online.co.uk) or visit our website [www.smi-online.co.uk/updates](http://www.smi-online.co.uk/updates) quoting the URN as detailed above your address on the attached letter.

**EARLY BIRD DISCOUNT**  Book by 31st October 2012 to receive a £300 off the conference price  
 Book by 30th November 2012 to receive a £100 off the conference price

### CONFERENCE PRICES

I would like to attend: (Please tick as appropriate)	Fee	Total
<input type="checkbox"/> Conference & Workshop	£2098.00 + VAT	£2517.60
<input type="checkbox"/> Conference only	£1499.00 + VAT	£1798.80
<input type="checkbox"/> Workshop only	£599.00 + VAT	£718.80

### PROMOTIONAL LITERATURE DISTRIBUTION

<input type="checkbox"/> Distribution of your company's promotional literature to all conference attendees	£999.00 + VAT	£1198.80
--	---------------	----------

### GROUP DISCOUNTS AVAILABLE

The conference fee includes refreshments, lunch, conference papers and access to the Document Portal containing all of the presentations.

### VENUE Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SR

Please contact me to book my hotel

Alternatively call us on +44 (0) 870 9090 711,  
email: [events@smi-online.co.uk](mailto:events@smi-online.co.uk) or fax +44 (0) 870 9090 712

### DOCUMENTATION

I cannot attend but would like to purchase access to the following Document

Portal/paper copy documentation	Price	Total
<input type="checkbox"/> Access to the conference documentation on the Document Portal	£499.00 + VAT	£598.80
<input type="checkbox"/> The Conference Presentations – paper copy (or only £300 if ordered with the Document Portal)	£499.00 -	£499.00

### PAYMENT

Payment must be made to **SMi Group Ltd**, and received before the event, by one of the following methods quoting reference **P-064** and the delegate's name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment:

- UK BACS** Sort Code 300009, Account 00936418
- Wire Transfer** Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU  
Swift (BIC): LOYDGB21013, Account 00936418  
IBAN GB48 LOYD 3000 0900 9364 18
- Cheque** We can only accept Sterling cheques drawn on a UK bank.
- Credit Card**  Visa  MasterCard  American Express  
All credit card payments will be subject to standard credit card charges.

Card No:

Valid From   /   Expiry Date   /

CVV Number    3 digit security on reverse of card, 4 digits for AMEX card

Cardholder's Name: \_\_\_\_\_

Signature: Date: \_\_\_\_\_

I agree to be bound by SMi's Terms and Conditions of Booking.

Card Billing Address (If different from above): \_\_\_\_\_

### VAT

VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document Portal and Literature Distribution for all UK customers and for those EU customers not supplying a registration number for their own country here: \_\_\_\_\_

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at [events@smi-online.co.uk](mailto:events@smi-online.co.uk)